A comparative study of the market potential of different cardiovascular drugs in the pharmaceutical industry
Summary :
Table of Contents
- Introduction
- Overview of Cipla
- History
- Vision and target
- Executive team
- Code of conducts
- Revenue distribution
- R&D infrastructure
- Milestones of Cipla
- Performance review
- Cipla in international business
- Global presence
- Strategic tie-ups
- Internal control system
- Expansion & modernization
- Business environment of Cipla
- Social responsibility
- Cipla's product
- Achievements & awards
- Cipla: Future outlook
- Valuation of Cipla
- SWOT analysis of Indian pharma industry
- SWOT analysis of Cipla
- Research objectives and methodology
- Data analysis & interpretation
- Suggestions & recommendations
- Bibliography
- Conclusion
Abstract
A sample size of 20 hospitals and 33 chemists was chosen from the region. The survey method chosen was pharmacy to pharmacy by conducting personal interview, the data collection was extended for over 45 days and 20 pharmacy in-charge and 33 chemists were interviewed and asked questions regarding their awareness, availability, prescriptions and the sale of cardiovascular injections (containing Amiodaron and Enoxaparin) like Amiodaron (Sanofi), Tachyre (Cipla), Clexane (Aventis), LMWX (Nicholas), Flothin (Ranbaxy), Enclex (cipla) etc. and cardiovascular medicines (containing Atorvastatin, Metoprolol, Torsemide and Telmisartan). It is found that on what doctors & hospitals would company focus. The data collected originally was on weekly basis and for the purpose of analysis of all the results on monthly basis. The research brought out the fact like the awareness level of the above brand, market coverage, market potential, sale, important hospitals and important doctors who prescribed these cardiovascular drugs. Cipla, originally founded as the Chemical, Industrial & pharmaceutical Laboratories is a prominent Indian pharmaceutical industry, best-known outside its home country for producing low-cost anti-AIDS drugs for HIV-positive patients in developing countries. Cipla makes drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions, and its products are distributed in more than 180 countries worldwide. Among the hundreds of generic medications it produces for international distribution are atorvastatin, amlopidine, fluoxetine, venlafaxine hydrochloride and metformin. The company was founded in 1935 by Khwaja Abdul Hamied, and its chairman today is Yusuf Hamied (b. 1936), the founder's eldest son. The journey began in 1973, when Cipla took the initiative to launch the 1st β-blocker in India, Propranalol under the brand name CIPLAR. Since then, over the last 3 decades, Cipla Vitalis has continued to excel in the field of cardiovascular therapies with new innovative products & services.
Latest in the category : Medical studies
3
An overview of digestive system in humans and digestive disorders
Term papers | 09/22/2009 | en | .doc | 8 pages
5
How can cardiac output be controlled physiologically and pharmacologically?
Term papers | 08/14/2009 | en | .doc | 7 pages
Most downloaded in the last 30 days : Medical studies
1
Case study: Early-episode psychosis as the onset of paranoid schizophrenia and the direction toward holistic and client-centered occupational therapy
Case study | 07/29/2009 | en | .doc | 7 pages
2
A medical case study concerning an elderly man with congestive heart failure
Term papers | 07/15/2009 | en | .doc | 7 pages
From the same author : Medical studies
4
World trade organization: Understanding its implementation in India
Term papers | 05/09/2009 | en | .doc | 14 pages
Change Currency
Our guarantee :
How it works?
Quality guaranteed
Refunds
Secure payment
Who are we ?
